Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.
This review (s=8) found that psychedelics (LSD, psilocybin) can aid in the recognition of emotions in facial expressions (REFE), which is thought to be a key aspect of social cognition. Psychedelics do this by modulating the activity of the amygdala.
Authors
- Jamie Hallak
- Rafael dos Santos
- Jaime Crippa
Published
Abstract
Background
Recognition of emotions in facial expressions (REFE) is a key aspect of social cognition. Anxiety and mood disorders are associated with deficits in REFE, and anxiolytics and antidepressants reverse these deficits. Recent studies have shown that serotonergic hallucinogens (i.e. ayahuasca, dimethyltryptamine, psilocybin, lysergic acid diethylamide [LSD], and mescaline) have anxiolytic and antidepressant properties, but their effects on REFE are not well understood. The purpose of the study was to conduct a systematic review analyzing the effects of serotonergic hallucinogens on REFE in humans.
Methods
Studies published in the PubMed, PsycINFO, and Web of Science databases until 19 October 2018 which analyzed the effects of serotonergic hallucinogens on REFE in humans were included.
Results
Of the 62 studies identified, 8 studies were included. Included studies involved the administration of a single or a few doses of LSD or psilocybin, and most trials were randomized and controlled with placebo. LSD and psilocybin reduced the recognition of negative emotions in most studies and modulated amygdala activity to these stimuli, which was correlated with antidepressive effects in patients. Both drugs were well tolerated.
Conclusions
Serotonergic hallucinogens reduced the recognition of negative emotions by modulating amygdala activity. Despite the small sample sizes, results suggest that serotonergic hallucinogens show promising beneficial effects on deficits in REFE.
Research Summary of 'Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.'
Introduction
Recognition of emotions in facial expressions (REFE) is a core component of social cognition and is impaired in several psychiatric conditions, notably anxiety and mood disorders. Earlier research has shown that deficits in REFE are linked to clinical features—social anxiety disorder involves hypervigilance to threatening expressions, for example—and that some anxiolytic and antidepressant treatments produce changes in emotional processing that may precede clinical improvement. MDMA has been robustly shown to reduce identification of negative emotions and to modulate amygdala and prefrontal activity, and recent preclinical and clinical work has suggested that classical serotonergic hallucinogens (LSD, psilocybin, ayahuasca/DMT, mescaline) have anxiolytic and antidepressant properties mediated via 5-HT2A receptor agonism in brain regions implicated in emotion processing. Rocha and colleagues set out to systematically review human experimental studies that directly examined the effects of serotonergic hallucinogens on REFE. The stated goal was to determine whether these compounds alter recognition of facial emotions and to summarise neurophysiological and clinical correlates, with attention to potential relevance for treating disorders characterised by REFE deficits such as depression and anxiety.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Rocha, J. M., Osório, F. L., Crippa, J. A. S., Bouso, J. C., Rossi, G. N., Hallak, J. E. C., & dos Santos, R. G. (2019). Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.. Therapeutic Advances in Psychopharmacology, 9. https://doi.org/10.1177/2045125319845774
References (16)
Papers cited by this study that are also in Blossom
Bedi, G., Hyman, D., De Wit, H. · Biological Psychiatry (2010)
´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)
Kirkpatrick, M. G., Lee, R., Wardle, M. C. et al. · Neuropsychopharmacology (2014)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Dos Santos, R. G., Bouso, J. C., Hallak, J. E. · Expert Review of Clinical Pharmacology (2018)
Kometer, M., Schmidt, A., Bachmann, R. et al. · Biological Psychiatry (2012)
Schmidt, A., Kometer, M., Bachmann, R. et al. · Psychopharmacology (2012)
Bernasconi, F. ;., Schmidt, A. ;., Pokorny, T. ;. et al. · Cerebral Cortex (2013)
Show all 16 referencesShow fewer
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Mueller, F., Lenz, C., Dolder, P. C. et al. · Translational Psychiatry (2017)
Roseman, L., Demetriou, L., Wall, M. B. et al. · Neuropharmacology (2018)
Stroud, J., Freeman, T. P., Leech, R. et al. · Psychopharmacology (2017)
Grimm, O., Kraehenmann, R., Preller, K. H. et al. · European Neuropsychopharmacology (2018)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Cited By (21)
Papers in Blossom that reference this study
Suay, D., Aicher, H. D., Kometer, M. et al. · NeuroImage (2025)
Solaja, I., Haldane, K., Mason, N. et al. · Neuroscience and Biobehavioral Reviews (2024)
Orłowski, P., Hobot, J., Ruban, A. et al. · Journal of Psychopharmacology (2023)
Rossi, G. N., Rocha, J. M., Osório, F. L. et al. · Journal of Clinical Psychopharmacology (2023)
Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)
Costa, M. A. · Journal of Psychoactive Drugs (2022)
Orłowski, P., Ruban, A., Szczypiński, J. et al. · Journal of Psychopharmacology (2022)
Balaet, M. · Frontiers in Neuroscience (2022)
Perry, C. M., Malina, M. · Psychopharmacology (2021)
Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)
Show all 21 papersShow fewer
Castelhano, J. M., Lima, G. M., Teixeira, M. et al. · Frontiers in Pharmacology (2021)
Healy, C. J., Lee, K. A. · Chronic Stress (2021)
Dos Santos, R. G., Osório, F. L., Rocha, J. M. et al. · Journal of Clinical Psychopharmacology (2021)
Bement, W., Banks, M. I., Zahid, Z. et al. · Molecular Biology of the Cell (2021)
Rodrigues, L. S., Rossi, G. N., Rocha, J. M. et al. · European Archives of Psychiatry and Clinical Neuroscience (2021)
Rocha, J. M., Rossi, G. N., de Lima Osório, F. et al. · Journal of Clinical Psychopharmacology (2021)
Bouso, J. C., Ona, G., Dos Santos, R. G. et al. · Advances in Experimental Medicine and Biology (2021)
Ferris, J. A., Nutt, D. J. · Drug Science Policy and Law (2020)
Heuschkel, K., Kuypers, K. P. C. · Frontiers in Psychiatry (2020)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2020)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.